← Leaderboards
Joshua Michael Lang
University Of Wisconsin-Madison
$8,279,603
Attributed
$14,903,514
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,483,485 · 14
By mechanism
R01$7,294,851 · 4
P01$3,363,793 · 3
UH3$3,290,318 · 2
UG3$1,629,672 · 1
P50$1,459,406 · 2
UH2$351,608 · 1
Top collaborators
- David J Beebe10 shared
- Andrew J Armstrong5 shared
- Scott M Berry5 shared
- Susan Halabi5 shared
- Dana Rathkopf5 shared
- Scott M. Dehm3 shared
- Shuang Zhao1 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- David J Beebe$20,083,426
- Wei Xu$10,169,679
- Megan E Spurgeon$643,505
- Heather B Neuman$3,392,239
- Jane Ellen Churpek$2,440,486
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingMalignant Neoplasm Of ProstateClinical TrialsTherapy ResistantTumorCellsMolecularProspectiveMalignant NeoplasmsFutureBiopsyResistanceSuccessGenetic TranscriptionTechnologyResponseTargeted TreatmentResearch PersonnelGenomicsNeoplasm Circulating CellsWisconsinGene ExpressionAndrogen ReceptorBiological
Grant awards (36)
The Molecular Drivers and Therapeutic Susceptibilities in Lineage State Transitions of Metastatic Prostate Cancer$2,579,971
P01 · FY2025 · CA · contact PI
Cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer$680,453
R01 · FY2025 · CA
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$651,191
R01 · FY2025 · CA · contact PI
Lineage Addiction in Prostate Cancer: Molecular Interactions and Translational Biomarkers$636,167
P01 · FY2025 · CA · contact PI
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer$400,761
P50 · FY2025 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$328,747
UH3 · FY2025 · CA · contact PI
Administrative Core$147,655
P01 · FY2025 · CA · contact PI
Career Enhancement Program$96,911
P50 · FY2025 · CA · contact PI
Circulating Biomarker Core$31,279
P30 · FY2025 · CA · contact PI
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics$724,178
UH3 · FY2024 · CA
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$625,914
R01 · FY2024 · CA · contact PI
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics$602,554
R01 · FY2024 · CA
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer$389,239
P50 · FY2024 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$318,930
UH3 · FY2024 · CA · contact PI
Career Enhancement Program$92,616
P50 · FY2024 · CA · contact PI
Circulating Biomarker Core$31,279
P30 · FY2024 · CA · contact PI
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics$777,500
UH3 · FY2023 · CA
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$695,050
R01 · FY2023 · CA · contact PI
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics$621,582
R01 · FY2023 · CA
Project 1: Tumor Microenvironment Initiators of the Metastatic Cascade in High-Risk Prostate Cancer$388,567
P50 · FY2023 · CA · contact PI
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$363,463
UH3 · FY2023 · CA · contact PI
Career Enhancement Program$91,312
P50 · FY2023 · CA · contact PI
Circulating Biomarker Core$31,279
P30 · FY2023 · CA · contact PI
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics$777,500
UH3 · FY2022 · CA
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics$620,020
R01 · FY2022 · CA
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$160,240
UH2 · FY2022 · CA · contact PI
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics$854,255
UG3 · FY2021 · CA
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics$634,266
R01 · FY2021 · CA
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$191,368
UH2 · FY2021 · CA · contact PI
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics$775,417
UG3 · FY2020 · CA
Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics$610,874
R01 · FY2020 · CA
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis$311,847
R01 · FY2018 · CA · contact PI
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis$311,847
R01 · FY2017 · CA · contact PI
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis$311,847
R01 · FY2016 · CA · contact PI
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis$311,847
R01 · FY2015 · CA · contact PI
VERSA: An Integrated, Multi-Endpoint Platform for Circulating Tumor Cell Analysis$305,559
R01 · FY2014 · CA · contact PI